摘要
目的评价更昔洛韦和喜炎平4种治疗方案对小儿疱疹性咽峡炎的有效性、安全性和经济性。方法将422例患儿随机分为对照组Ⅰ、对照组Ⅱ、静脉组、雾化组,分别观察其疗效和不良反应,并运用药物经济学成本-效果分析法进行分析。结果对照组Ⅰ、对照组Ⅱ、静脉组、雾化组成本分别是(853.52±265.42)元、(707.45±223.10)元、(1 119.65±398.45)元、(987.88±305.46)元,有效率分别是81.13%,66.66%,95.24%,94.34%,不良反应发生率分别是11.32%,5.71%,13.33%,7.55%,成本-效果比(C/E)分别是10.52±3.27,10.61±3.34,11.75±4.18,10.47±3.24;对照组Ⅰ、静脉组、雾化组相对于对照组Ⅱ的增量成本-效果比(ΔC/ΔE)分别是10.09±2.92,10.13±2.98,14.42±6.13。结论雾化组为较佳的给药方案。
Objective To evaluate the effect,economy and safety of 4 different therapeutic schemes for children herpangina.Methods The clinical data in 422 cases of children herpangina were collected and randomly divided into four groups,control group Ⅰ,control group Ⅱ,intravenous drip group and atomization group.The therapeutic effects and adverse reactions were observed.The data were evaluated using the pharmacoeconomic cost-effectiveness analysis.Results The costs were(853.52±265.42) Yuan for the control group Ⅰ,(707.45±223.10) Yuan for the control group Ⅱ,(1 119.65±398.45) Yuan for the intravenous drip group and(987.88±305.46) Yuan for the atomization group,respectively.The effective rates were 81.13%,66.66%,95.24%,94.34%,respectively.The cost-effectiveness ratios were 10.52±3.27,10.61±3.34,11.75±4.18 and 10.47±3.24 respectively.The incremental cost-effectiveness ratios(ΔC/ΔE) were 10.09±2.92,10.13±2.98 and 14.42±6.13 respectively.Conclusion Among the 4 schemes,atomization group is the better one.
出处
《中国药业》
CAS
2011年第19期48-50,共3页
China Pharmaceuticals